Adicet Bio, Inc. (ACET)
$
0.78
+0.03 (3.85%)
Key metrics
Financial statements
Free cash flow per share
-1.0684
Market cap
61.2 Million
Price to sales ratio
0
Debt to equity
0.1006
Current ratio
9.3368
Income quality
0.8091
Average inventory
0
ROE
-0.5905
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies targeting cancer and other diseases. The operating expenses amount to $127,615,000.00 encompassing various operational costs incurred in the pursuit of advancing its innovative therapies. With an emphasis on engineered gamma delta T cells that integrate chimeric antigen receptors and T cell receptor-like antibodies, Adicet Bio enhances selective tumor targeting while facilitating both innate and adaptive anti-tumor immune responses. The EBITDA ratio is 0.00 highlighting the company's operational efficiency amid research and development efforts. Despite these advancements, the company reported a net loss of -$117,122,000.00 indicating challenges in its operations. Furthermore, the weighted average number of shares outstanding is 87,866,435.00 reflecting the company's shareholder base and financial structure. Adicet Bio's stock, identified with the symbol 'ACET' in the market, represents an investment opportunity in the biotechnology sector. Affordability is a key consideration for investors, as the stock is affordable at $0.78 making it suitable for budget-conscious investors. The stock has an average trading volume of 499,453.00 indicating moderate liquidity in the marketplace. With a market capitalization of $64,397,695.00 the company is classified as a small-cap player, which often attracts specific investment strategies. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its innovative approaches. Furthermore, it belongs to the Healthcare sector, driving innovation and growth through its targeted therapeutic developments. With its focus on advancing gamma delta T cell therapies and fostering a robust pipeline, Adicet Bio, Inc. stands as a noteworthy entity in the ongoing fight against cancer and other diseases while navigating the complexities of the biotech industry.
Is Adicet Bio, Inc. (ACET) a good investment?
Investing in Adicet Bio, Inc. (ACET) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Adicet Bio, Inc. (ACET)'s stock forecast?
Analysts predict Adicet Bio, Inc. stock to fluctuate between $0.45 (low) and $1.70 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Adicet Bio, Inc.'s market capitalization?
As of 2025-07-14, Adicet Bio, Inc.'s market cap is $64,397,695, based on 82,709,600 outstanding shares.
How does Adicet Bio, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Adicet Bio, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Adicet Bio, Inc. pay dividends?
Adicet Bio, Inc. pays dividends. The current dividend yield is 0.14%, with a payout of $0.00 per share.
How can I buy Adicet Bio, Inc. (ACET) stock?
To buy Adicet Bio, Inc. (ACET) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACET. Place an order (Market, Limit, etc.).
What is the best time to invest in Adicet Bio, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Adicet Bio, Inc. stock ever split?
Adicet Bio, Inc.'s last stock split was 1:7 on 2020-09-16.
How did Adicet Bio, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.33 | Growth: -59.82%.
Where can I find Adicet Bio, Inc.'s investor relations reports?
Visit https://www.adicetbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Adicet Bio, Inc.?
You can explore historical data from here
What is the all-time high and low for Adicet Bio, Inc. stock?
All-time high: $21.87 (2022-11-11) | All-time low: $0.45 (2025-04-10).
What are the key trends affecting Adicet Bio, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
2 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York. Details of the event are as follows: Date: Wednesday, June 4, 2025 Time: 4:20.
zacks.com
2 months ago
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
businesswire.com
2 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025. “We are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon,” said Chen Schor, President and Chief Executive Officer.
businesswire.com
2 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 206,800 shares of Adicet's common stock with an exercise price of $0.66 per.
businesswire.com
3 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, in New Orleans, LA. Details of the oral presentation are as follows: Title: ADI-270, an Armo.
businesswire.com
3 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. “We are honored to welcome Michael t.
businesswire.com
3 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025. Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet's common stock with an exercise price of $0.76 per sh.
businesswire.com
3 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025. Details of the event are as follows: Panel: “CAR T Approaches in the Autoimmune Space.
businesswire.com
4 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2024. “In 2025 we plan to continue advancing our gamma delta 1 CAR T cell therapy programs, achieving key milestones and reporting preliminary data in autoimmune and.
businesswire.com
4 months ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Ti.
See all news
